Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I

Diabetologia

Volumn 51, Issue 6, 2008, Pages 1008-1017

  Nobecourt E ^a   Zeng, J ^a   Davies, M J ^a,b   Brown, B E ^a   Yadav, S ^a   Barter, P J ^a,b   Rye, K A ^a,b,c  

^a HEART RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alagebrium; Aminoguanidine; ApoA I; Apolipoprotein A I; Glycation; HDL; LCAT; Lecithin:cholesterol acyltransferase; Metformin; Pyridoxamine

Indexed keywords

ALAGEBRIUM; AMINOGUANIDINE; APOLIPOPROTEIN A1; ARGININE; CROSS LINKING REAGENT; HIGH DENSITY LIPOPROTEIN; INSULIN SENSITIZING AGENT; LYSINE; METFORMIN; METHYLGLYOXAL; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PYRIDOXAMINE; TRYPTOPHAN;

ARTICLE; CONTROLLED STUDY; GLYCATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN FUNCTION;

APOLIPOPROTEIN A-I; ARGININE; CROSS-LINKING REAGENTS; GLYCOSYLATION; GUANIDINES; HUMANS; LIPOPROTEINS, HDL; LYSINE; METFORMIN; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; PYRIDOXAMINE; PYRUVALDEHYDE; THIAZOLES; TRYPTOPHAN;

EID: 43049144209     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-008-0986-z     Document Type: Article

References (54)

1. Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653
2. Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF (1999) Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 22:1543-1548
3. Schiel R, Franke S, Appel T et al (2004) Improvement of the quality of diabetes control and decrease in the concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus: results from a 10 year-prospective, population-based survey on the quality of diabetes care in Germany (JEVIN). Eur J Med Res 9:391-399
4. Thorpe SR, Baynes JW (2003) Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 25:275-281
5. Meng J, Sakata N, Takebayashi S et al (1998) Glycoxidation in aortic collagen from STZ-induced diabetic rats and its relevance to vascular damage. Atherosclerosis 136:355-365
6. Schmidt AM, Hori O, Chen JX et al (1995) Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395-1403
7. Hammes HP, Alt A, Niwa T et al (1999) Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 42:728-736
8. Makita Z, Radoff S, Rayfield EJ et al (1991) Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325:836-842
9. Lapolla A, Flamini R, Dalla Vedova A et al (2003) Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new GC/MS method. Clin Chem Lab Med 41:1166-1173
10. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62:707-714
11. Lewis GF, Rader DJ (2005) New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96:1221-1232
12. Kontush A, Chantepie S, Chapman MJ (2003) Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 23:1881-1888
13. Nicholls SJ, Dusting GJ, Cutri B et al (2005) Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111:1543-1550
14. Mineo C, Deguchi H, Griffin JH, Shaul PW (2006) Endothelial and antithrombotic actions of HDL. Circ Res 98:1352-1364
15. Spieker LE, Sudano I, Hurlimann D et al (2002) High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105:1399-1402
16. Tso C, Martinic G, Fan WH, Rogers C, Rye KA, Barter PJ (2006) High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol 26:1144-1149
17. Passarelli M, Tang C, McDonald TO et al (2005) Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells. Diabetes 54:2198-2205
18. Ohta T, Nishiyama S, Nakamura T, Saku K, Maung KK, Matsuda I (1998) Predominance of large low density lipoprotein particles and lower fractional esterification rate of cholesterol in high density lipoprotein in children with insulin-dependent diabetes mellitus. Eur J Pediatr 157:276-281
19. Nobecourt E, Jacqueminet S, Hansel B et al (2005) Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 48:529-538
20. Rohrer L, Hersberger M, von Eckardstein A (2004) High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 15:269-278
21. Nobecourt E, Davies MJ, Brown BE et al (2007) The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia 50:643-653
22. Osborne JC Jr (1986) Delipidation of plasma lipoproteins. Methods Enzymol 128:213-222
23. Weisweiler P (1987) Isolation and quantitation of apolipoproteins A-I and A-II from human high-density lipoproteins by fast-protein liquid chromatography. Clin Chim Acta 169:249-254
24. Matz CE, Jonas A (1982) Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J Biol Chem 257:4535-4540
25. Rye KA, Garrety KH, Barter PJ (1993) Preparation and characterization of spheroidal, reconstituted high-density lipoproteins with apolipoprotein A-I only or with apolipoprotein A-I and A-II. Biochim Biophys Acta 1167:316-325
26. Piran U, Morin RJ (1979) A rapid radioassay procedure for plasma lecithin-cholesterol acyltransferase. J Lipid Res 20:1040-1043
27. Knott HM, Brown BE, Davies MJ, Dean RT (2003) Glycation and glycoxidation of low-density lipoproteins by glucose and low-molecular mass aldehydes. Formation of modified and oxidized particles. Eur J Biochem 270:3572-3582
28. Sparks DL, Phillips MC (1992) Quantitative measurement of lipoprotein surface charge by agarose gel electrophoresis. J Lipid Res 33:123-130
29. Stahler F, Gruber W, Stinshoff K, Roschlau P (1977) A practical enzymatic cholesterol determination. [Article in German] Med Lab (Stuttg) 30:29-37
30. Takayama M, Itoh S, Nagasaki T, Tanimizu I (1977) A new enzymatic method for determination of serum choline-containing phospholipids. Clin Chim Acta 79:93-98
31. Smith PK, Krohn RI, Hermanson GT et al (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85
32. Rainwater DL, Andres DW, Ford AL, Lowe F, Blanche PJ, Krauss RM (1992) Production of polyacrylamide gradient gels for the electrophoretic resolution of lipoproteins. J Lipid Res 33:1876-1881
33. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629-1632
34. Khatami M, Suldan Z, David I, Li W, Rockey JH (1988) Inhibitory effects of pyridoxal phosphate, ascorbate and aminoguanidine on nonenzymatic glycosylation. Life Sci 43:1725-1731
35. Price DL, Rhett PM, Thorpe SR, Baynes JW (2001) Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 276:48967-48972
36. Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N, Nadler JL (2000) Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 301:65-77
37. Ruggiero-Lopez D, Lecomte M, Moinet G, Patereau G, Lagarde M, Wiernsperger N (1999) Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 58:1765-1773
38. Battah S, Ahmed N, Thornalley PJ (2002) Kinetics and mechanism of the reaction of metformin with methylglyoxal. Int Congr Ser 1245:355-356
39. Voziyan PA, Khalifah RG, Thibaudeau C et al (2003) Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. J Biol Chem 278:46616-46624
40. Voziyan PA, Metz TO, Baynes JW, Hudson BG (2002) A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 277:3397-3403
41. Stitt A, Gardiner TA, Alderson NL et al (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51:2826-2832
42. Degenhardt TP, Alderson NL, Arrington DD et al (2002) Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61:939-950
43. Machado AP, Pinto RS, Moyses ZP, Nakandakare ER, Quintao EC, Passarelli M (2006) Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products. Int J Biochem Cell Biol 38:392-403
44. Hoang A, Murphy AJ, Coughlan MT et al (2007) Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 50:1770-1779
45. Brown BE, Mahroof FM, Cook NL, van Reyk DM, Davies MJ (2006) Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins. Diabetologia 49:775-783
46. Forbes JM, Yee LT, Thallas V et al (2004) Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53:1813-1823
47. Zieman SJ, Melenovsky V, Clattenburg L et al (2007) Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens 25:577-583
48. Bolton WK, Cattran DC, Williams ME et al (2004) Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 24:32-40
49. Freedman BI, Wuerth JP, Cartwright K et al (1999) Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 20:493-510
50. Vasan S, Zhang X, Kapurniotu A et al (1996) An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382:275-278
51. Yang S, Litchfield JE, Baynes JW (2003) AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch Biochem Biophys 412:42-46
52. Thornalley PJ, Minhas HS (1999) Rapid hydrolysis and slow alpha,beta-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links. Biochem Pharmacol 57:303-307
53. Nanjee MN, Crouse JR, King JM et al (1996) Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler Thromb Vasc Biol 16:1203-1214
54. Chetiveaux M, Lalanne F, Lambert G, Zair Y, Ouguerram K, Krempf M (2006) Kinetics of prebeta1 HDL and alphaHDL in type II diabetic patients. Eur J Clin Invest 36:29-34